has been cited by the following article(s):
|
[1]
|
A 25-year-female with Diffuse Intrinsic Pontine Glioma Surviving for More than Nine Years Following Treatment with Antineoplastons
|
|
Cancer …,
2022 |
|
|
|
|
[2]
|
Cell Differentiation Agent Formulations to Win the War on Cancer
|
|
Cancer Sci Res,
2022 |
|
|
|
|
[3]
|
Winning Formulas to Fulfill Cancer Moonshot
|
|
Int J Res Oncol,
2022 |
|
|
|
|
[4]
|
Long-term survival (23 years) in a 26-year-old male after Antineoplaston therapy for a progressive, diffuse intrinsic pontine glioma: A case report
|
|
Int J Brain Disord …,
2021 |
|
|
|
|
[5]
|
Resolution of clinical signs, a complete response, and long-term survival (> 23 Years) in a 3 and ½ month female with a newly diagnosed diffuse intrinsic …
|
|
Biomed Res,
2021 |
|
|
|
|
[6]
|
Development of Synthetic Cell Differentiation Agent Formulations for the Prevention and Therapy of Cancer via Targeting of Cancer Stem Cells
|
|
Cancer Studies and Therapeutics,
2019 |
|
|
|
|
[7]
|
Destabilization of Abnormal Methylation Enzymes: Nature's Way to Eradicate Cancer Stem Cells. On J Complement & Alt Med. 2 (5): 2019
|
|
2019 |
|
|
|
|
[8]
|
A Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Brainstem Gliomas. The Report on Non-Diffuse Intrinsic Pontine Glioma (Protocol BT-11)
|
|
Journal of Cancer Therapy,
2015 |
|
|
|
|
[9]
|
Newly-Diagnosed Multicentric Pilocytic Astrocytoma: Complete Response and> 22 Years Survival in a Six Year and Nine-Month-Old Female Treated with …
|
|
|
|
|
|
|
[1]
|
A Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Brainstem Gliomas. The Report on Non-Diffuse Intrinsic Pontine Glioma (Protocol BT-11)
Journal of Cancer Therapy,
2015
DOI:10.4236/jct.2015.64036
|
|
|
|